

## **Gypenosides attenuate retinal degeneration in a zebrafish retinitis pigmentosa model**

Alhasani, Reem Hasaballah; Zhou, Xinzhi; Biswas, Lincoln; Li, Xing; Reilly, James; Zeng, Zhihong; Shu, Xinhua

*Published in:*  
Experimental Eye Research

*DOI:*  
[10.1016/j.exer.2020.108291](https://doi.org/10.1016/j.exer.2020.108291)

*Publication date:*  
2020

*Document Version*  
Author accepted manuscript

[Link to publication in ResearchOnline](#)

### *Citation for published version (Harvard):*

Alhasani, RH, Zhou, X, Biswas, L, Li, X, Reilly, J, Zeng, Z & Shu, X 2020, 'Gypenosides attenuate retinal degeneration in a zebrafish retinitis pigmentosa model', *Experimental Eye Research*, vol. 201, 108291. <https://doi.org/10.1016/j.exer.2020.108291>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

1 **Gyenosides attenuate retinal degeneration in a zebrafish retinitis pigmentosa model**

2 Reem Hasaballah Alhasani<sup>1,4</sup>, Xinzhi Zhou<sup>1</sup>, Lincoln Biswas<sup>1</sup>, Xing Li<sup>5</sup>, James Reilly<sup>1</sup>, Zhihong Zeng<sup>2,\*</sup>  
3 and Xinhua Shu<sup>1,3,5\*</sup>

4 <sup>1</sup>Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow G4

5 OBA, United Kingdom

6 <sup>2</sup>College of Biological and Environmental Engineering, Changsha University, Changsha, Hunan

7 410022, P. R. China

8 <sup>3</sup>Department of Vision Science, Glasgow Caledonian University, Glasgow G4 OBA, United Kingdom

9 <sup>4</sup>Department of Biology, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi

10 Arabia

11 <sup>5</sup>School of Basic Medical Sciences, Shaoyang University, Shaoyang, Hunan 422000, P. R. China

12

13 \* Corresponding authors: z20181201@ccsu.edu.cn; [Xinhua.Shu@gcu.ac.uk](mailto:Xinhua.Shu@gcu.ac.uk)

14

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 Retinitis pigmentosa (RP) is a collection of heterogenous genetic retinal disorders resulting in  
26 cumulative retinal deterioration involving progressive loss of photoreceptors and eventually in  
27 total blindness. Oxidative stress plays a central role in this photoreceptor loss. Gypenosides (Gyp)  
28 are the main functional component isolated from the climbing vine *Gynostemma pentaphyllum*  
29 and have been shown to defend cells against the effects of oxidative stress and inflammation,  
30 providing protection in experimentally-induced optic neuritis. The zebrafish model has been used  
31 to investigate a range of human diseases. Previously we reported early retinal degeneration in a  
32 mutant zebrafish line carrying a point-nonsense mutation in the retinitis pigmentosa GTPase  
33 regulator interacting protein 1 (*rpgrip1*) gene that is mutated in RP patients. The current study  
34 investigated the potential protective effects of Gyp against photoreceptor degeneration in the  
35 *Rpgrip1* deleted zebrafish. *Rpgrip1* mutant zebrafish were treated with 5µg/ml of Gyp in E3  
36 medium from 6 hours post fertilization (hpf) till 1 month post fertilization (mpf). *Rpgrip1* mutant  
37 zebrafish treated with 5µg/mL of Gyp showed a significant decrease by 68.41% (p=0.0002) in  
38 photoreceptor cell death compared to that of untreated mutant zebrafish. Expression of  
39 antioxidant genes *catalase*, *sod1*, *sod2*, *gpx1*, *gclm*, *nqo-1* and *nrf-2* was significantly decreased in  
40 *rpgrip1* mutant zebrafish eyes by 61.51%, 77.40%, 60.11%, 81.17%, 72.07%, 78.95% and 85.42%  
41 (all p<0.0001), respectively, when compared to that of wildtype zebrafish; superoxide dismutase  
42 and catalase activities, and glutathione levels in *rpgrip1* mutant zebrafish eyes were significantly  
43 decreased by 87.21%, 21.55% and 96.51% (all p<0.0001), respectively. There were marked  
44 increases in the production of reactive oxygen species (ROS) and malondialdehyde (MDA) by

45 2738.73% and 510.69% (all  $p < 0.0001$ ), respectively, in *rpgr1* mutant zebrafish eyes; expression  
46 of pro-inflammatory cytokines IL-1 $\beta$ , IL-6 and TNF- $\alpha$  was also significantly increased by 150.11%,  
47 267.79% and 190.72% (all  $p < 0.0001$ ), respectively, in *rpgr1* mutant zebrafish eyes, compared to  
48 that of wildtype zebrafish. Treatment with Gyp significantly counteracted these effects. This study  
49 indicates that Gyp has a potential role in the treatment of RP.

50 **Keywords:** Retinitis pigmentosa; RPGRIP1; photoreceptor death; zebrafish; Gypenosides

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

## 70 1. Introduction

71 Retinitis pigmentosa (RP, MIM# 268000) is the term applied to a diverse range of inherited retinal  
72 disorders characterised by initial death of rod photoreceptors followed by the death of cone  
73 photoreceptors. RP is one of the most common retinal dystrophies, affecting 1 in 3000-4000  
74 people worldwide (Petra-Silva and Linden, 2014; Phelan and Bok, 2000; Raghupathy et al., 2013).  
75 Leber congenital amaurosis (LCA), the congenital version of RP, was first recognised and described  
76 by Leber (1869). LCA is perhaps the severest form of RP, affecting 1 in 40,000-80,000 worldwide  
77 and causing significant visual impairment within one year of birth (Sherwin et al., 2008; Stone,  
78 2007). Characterisation of LCA is based on its clinical features: photophobia, sensory nystagmus,  
79 early severe visual loss, absent or reduced electroretinogram (ERG) waveform, and amaurotic  
80 pupils (Stone, 2007).

81 Mutations in the Retinitis Pigmentosa GTPase Regulator Interacting Protein 1 (*RPGRIP1*)  
82 gene cause LCA (LCA6) (Dryja et al., 2001; Gerber et al., 2001), juvenile RP (Booij et al., 2005), late  
83 onset cone-rod dystrophy (CORD13) in humans (Hameed et al., 2003; Huang et al., 2013; Khan et  
84 al., 2013) and cone-rod dystrophy in dogs (Mellersh et al., 2013). Around 5% of all LCA cases is  
85 thought to be caused by mutations in the *RPGRIP1* gene (Kumaran et al., 2017). Depletion of  
86 *RPGRIP1* in human retinal pigment epithelial (RPE) cells causes cilia defects and abnormal  
87 cytoskeleton (Patnaik et al., 2018). Loss of *RPGRIP1* in mice results in developmental defects in  
88 photoreceptor outer segments, mislocalization of rhodopsin, and early retinal degeneration (Won  
89 et al. 2009; Zhao et al., 2003). Recently we have characterized a mutant zebrafish line that carries  
90 a nonsense homozygous mutation in the *rpgrip1* gene. The mutant zebrafish demonstrate defects

91 in the development of the rod outer segment and in the trafficking of ciliary protein, early retinal  
92 degeneration and impaired visual function (Raghupathy et al., 2017).

93 *Gynostemma pentaphyllum* (*G. pentaphyllum*) Makino (Jiaogulan in Chinese) is a  
94 herbaceous vine plant – more accurately a kind of cucurbitaceous liana (gourd family with woody  
95 vines to support its growth) – that is widely used in traditional medicine throughout Asia, including  
96 the mountainous regions of Vietnam, Japan, Korea and China. *G. pentaphyllum* Makino contains a  
97 variety of compounds including saponins, carotenoids, chlorophylls, flavonoids, polysaccharides,  
98 sterols, amino acids, vitamins and minerals (Razmovski-Naumovski et al., 2005). Gypenosides  
99 (Gyp), the dammarane-type saponins extract derived from the *G. pentaphyllum* (Thunb) Makino,  
100 are yellow in colour and bitter tasting, and have anti-diabetic, anti-hyperlipidemic , anti-tumour,  
101 anti-oxidative and anti-inflammatory properties (Li et al., 2019). We recently demonstrated that  
102 Gyp protected RPE cells from H<sub>2</sub>O<sub>2</sub>-induced oxidative damage and inflammation (Alhasani et al.,  
103 2018).

104 Current therapeutic strategies for RP include gene therapy, cell therapy, retinal prostheses  
105 and pharmacological approaches (Dias et al., 2018). High genetic heterogeneity of RP and the  
106 complexity of photoreceptor degeneration pathways make RP treatment extraordinarily  
107 challenging. Oxidative stress has been implicated in the progression of RP. Treatment with  
108 antioxidants has been shown to reduce oxidative damage and preserve photoreceptor function in  
109 RP animal models (Komeima et al., 2006; Lee et al., 2011; Shen et al., 2005). There is a close link  
110 between oxidative stress and inflammation. Mouse RP models exhibit increased proinflammatory  
111 cytokines and chemokines preceding photoreceptor degeneration (Karlstetter et al., 2015; Yoshida

112 et al., 2013a; Xun et al., 2019). RP patients also have significantly higher levels of proinflammatory  
113 cytokines and chemokines in the vitreous fluid (Yoshida et al., 2013b). Microglial activation has  
114 been observed in the retinas of RP patients and RP rodent models and is associated with rod cell  
115 death (Gupta et al., 2003; Karlstetter et al., 2015; Zhao et al., 2015). Activated microglia  
116 phagocytose pre-apoptotic rod cells and secrete proinflammatory cytokines, which exacerbates  
117 rod death in RP mouse models; by contrast, inhibition of microglial activation attenuates rod cell  
118 death (Zhao et al., 2015). Antioxidants and anti-inflammatory agents offer a therapeutic option  
119 (Guadagni et al., 2015), and so there is a pressing need to identify novel anti-oxidative and  
120 anti-inflammation agents for the treatment of RP. In the current study we appraised the  
121 therapeutic potential of Gyp for RP by using it to treat *rpgr1p1* mutant zebrafish and investigating  
122 subsequent biochemical and histological changes. We found that Gyp treatment delayed  
123 photoreceptor death, increased antioxidant capacity and inhibited endoplasmic reticulum (ER)  
124 stress and inflammation.

## 125 **2. Materials and methods**

### 126 *2.1. Toxicity assay*

127 All animal work received approval from the UK Home Office with Project licence PPL 70/8697.  
128 Gypenosides (Gyp), containing several gypenoside molecules, were purchased from Xi'an Jiatian  
129 Biotech Co. Ltd, China with 98% purity and dissolved in 100% Dimethyl sulfoxide (DMSO) as a stock  
130 (10 mg/mL). To determine the toxicity of Gyp in zebrafish embryonic stages, toxicity assay was  
131 carried out using previously described methods (Scholz et al., 2008). Zebrafish embryos at 6 hours  
132 post fertilization (hpf) were treated at 28 °C in twenty-four-well plates (10 embryos/well)  
133 containing 500 µl/well of Gyp at concentrations of 0, 2.5, 5.0, 15.0, 25.0 and 50.0 µg/ml in E3

134 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl<sub>2</sub>, 0.33 mM MgSO<sub>4</sub>). Mortality, heartbeat and  
135 hatching were recorded at 48, 72, 96 and 120 hpf. Heartbeat measurement was performed by  
136 putting individual embryos into E3 medium on a glass slide and visually counting ventricle beating  
137 (beats per minutes, BPM) under Evos microscope.

## 138 *2.2. Zebrafish treatment*

139 To investigate whether Gyp can inhibit or delay photoreceptor degeneration, *rpgr1* mutant  
140 embryos at 6 hpf were treated with Gyp in E3 medium till one month post fertilization (mpf).  
141 There were 3 groups: wildtype in E3 medium (0.05 % DMSO), *rpgr1* mutants in E3 medium  
142 (0.05 % DMSO), and *rpgr1* mutants treated with Gyp (5 µg /mL in 0.05% DMSO). The treatment  
143 was carried out in 60mm×15mm petri dishes in which the sibling and *rpgr1* mutant embryos (6  
144 hpf) were incubated at 28°C in 4 mL E3 medium with or without Gyp (15 embryos/petri dish in  
145 triplicates). After 5 days, the embryos were transferred to 1-litre water tanks (15 fish/tank in 100  
146 ml E3 medium) and kept at 24°C in the zebrafish facility for 25 days. During the treatment, fish  
147 were fed with ZM-100 fry food and brine shrimp (Zebrafish Management Ltd, UK). E3 medium  
148 (0.05 % DMSO) with or without Gyp (5µg /mL) was changed every two days. After the treatment,  
149 zebrafish were killed using Schedule one method and eyes were dissected for further examination.

## 150 *2.3. Measurement of reactive oxygen species (ROS)*

151 Eyes from wildtype, untreated and Gyp-treated *rpgr1* mutant zebrafish at 1mpf were collected  
152 and homogenized using the FastPrep®-24 homogenizer (MP Biomedicals, UK) on ice in lysis buffer  
153 containing 1 mM MgCl<sub>2</sub>, 20 mM HEPES, 0.32 mM sucrose, and 0.5 mM phenylmethylsulfonyl  
154 fluoride (PMSF, pH 7.4). The lysates were centrifuged at 10,000Xg for 5 minutes at 4°C and the  
155 supernatants were treated with Dichloro-dihydro-fluorescein Diacetate (DCFH-DA) solution (20



156  $\mu\text{g/ml}$ ,  $8.3 \mu\text{l/well}$ ) in 96-well plates and incubated in darkness at  $37^\circ\text{C}$  for 30 min. The fluorescent  
157 signal was measured using the Fluostar Optima microplate reader (BMG-labtech) at 485 nm  
158 (excitation) and 525 nm (emission). The ROS level was calculated as previously described  
159 (Alhasasni et al., 2018).

#### 160 *2.4. Histology and immunohistochemistry (IHC)*

161 After one month of treatment, zebrafish eyes were dissected, fixed at  $4^\circ\text{C}$  for 24 hours in 4%  
162 paraformaldehyde (PFA) solution, then washed with PBS twice, dehydrated with ethanol and  
163 embedded in paraffin to make tissue wax blocks for histology; alternatively, the eyes were  
164 incubated with 5%, 15% or 30% sucrose for 2 hours and then embedded in Optimal Cutting  
165 Temperature (OCT) compound for cryosections. Eye samples of  $8 \mu\text{m}$  thickness were sectioned by  
166 microtome or cryotome. For histology, sections were dewaxed and stained with  
167 haematoxylin-eosin. For measurement of the photoreceptor layer, five eyes from five individual  
168 fish from each group were used, two retinal sections of each eye were selected and images were  
169 taken from inferior sides. Thickness of the photoreceptor layer was measured using Image J  
170 software at the location 0.4 mm from the optic nerve head. For IHC, cryosections were blocked for  
171 30 minutes in 2% bovine serum albumin (BSA)/PBS and incubated with primary antibody  
172 (anti-rhodopsin, Cat. ab98887, Abcam, 1:500 dilution) in 2% BSA/PBS at room temperature for 2  
173 hours. The sections were washed three times (5 minutes/each) with PBS and then incubated with  
174 secondary antibody (goat anti-mouse IgG FITC-conjugated, Cat. F0257, Sigma, UK (1:500 dilution)  
175 in 2% BSA/PBS at room temperature for 1 hour. After washing with PBS five times (5  
176 minutes/each), the sections were mounted with Vectashield 4',6-diamidino-2-phenylindole (DAPI)

177 (D9542-Sigma, UK). Images were taken with ZEISS LSM 800 confocal microscopy. To quantify the  
178 rhodopsin fluorescence signal, 10 retinal sections from five eyes (two sections/each eye) were  
179 collected from the control (wildtype zebrafish), *rpgr1* mutants, or *rpgr1* mutants treated with  
180 Gyp. In each section, one region (10  $\mu\text{m}\times 10\ \mu\text{m}$ , under  $\times 400$  magnification) in the superior side  
181 (0.4 mm from the optic nerve head) and one region (10  $\mu\text{m}\times 10\ \mu\text{m}$ , under  $\times 400$  magnification) in  
182 the inferior side (0.4 mm from the optic nerve head) were chosen for quantification of fluorescent  
183 signals with ImageJ software. The signals from both the superior region and the inferior region  
184 were averaged for the final calculation.

#### 185 *2.5. Gene expression*

186 Total RNA was extracted from 20 eyes of wildtype, *rpgr1* mutant, or Gyp-treated *rpgr1* mutant  
187 zebrafish at 1 mpf by using the TRIzol reagent (Sigma, UK) according to the manufacturer's  
188 guidance. cDNA synthesis was performed using High-Capacity cDNA Reverse Transcription Kit  
189 (Applied Biosystems, UK). Quantitative real-time polymerase chain reaction (qRT-PCR) was carried  
190 out using Platinum<sup>®</sup> SYBR<sup>®</sup> Green QPCR SuperMix-UDG w/ROX kit (ThermoFisher Scientific, UK)  
191 following the manufacturer's protocol. The primers for qRT-PCR are listed in Table S1.  $\beta$ -actin was  
192 used to normalize mRNA levels of candidate genes.

#### 193 *2.6. Measurement of activities of superoxide dismutase (SOD) and catalase (CAT) and* 194 *quantification of glutathione (GSH) and malondialdehyde (MDA) levels*

195 Activities of SOD and CAT and levels of GSH and MDA were measured in zebrafish eye samples  
196 using individual commercial kits (STA-340 for SOD, STA-341 for CAT, STA-312 for GSH and STA-330  
197 for MDA from Cell Biolabs) following the manufacturer's instructions.

#### 198 *2.7. Western blotting*

199 Twenty eyes from the groups of wildtype, *rpgr1* mutant and Gyp-treated *rpgr1* mutant  
200 zebrafish were homogenized in protein lysis buffer (T-PER, Thermo Fisher Scientific UK) using a  
201 FastPrep®-24 homogenizer (MP Biomedicals) on ice. Concentration of protein samples was  
202 measured by a Bradford assay. 100µg of individual protein samples was loaded in the pre-cast  
203 protein gel (Cat. No. 4569034, Bio-Rad) then electrophoresed for 45-60mins at 200V in the running  
204 buffer. The gel was removed from the electrophoresis apparatus and assembled into a sandwich  
205 containing three sponges, filter paper, pre-cast protein gel, nitrocellulose membrane, filter paper  
206 and three more sponges. The sponge-gel-membrane sandwich was then placed into a transfer  
207 cassette in the Wet Tank Transfer System (Cat. No. EI9051, Thermo Fisher Scientific) containing the  
208 transfer buffer to transfer the protein from the pre-cast protein gel onto the nitrocellulose  
209 membrane under 175mA for 90 minutes. The nitrocellulose membrane was blocked with Tris  
210 buffered saline with 0.1% Tween-20 (TBST) and 5% (w/v) non-fat dry milk for 2 hours at room  
211 temperature. The membrane was incubated with primary antibody (anti-acetylated tubulin  
212 antibody, Cat. T7451, Sigma, UK, 1:1000 dilution, anti-Caspase-3 antibody, Cat. ABIN1883652,  
213 Antibodies-online, UK, 1:1000 or anti-TNF-α antibody, Cat. ABIN1884227, Antibodies-online, UK,  
214 1:1000 dilution) in TBST with 5% (w/v) non-fat dry milk for two hours. After washing three times  
215 with TBST, the membrane was incubated with secondary antibody (goat anti-rabbit antibody, Cat.  
216 926–32211 or donkey anti-mouse antibody, Cat. 926–68072, 1:10,000 diluted in TBST with 5%  
217 non-fat dry milk) at room temperature for 2 hours. The membrane was washed five times (5  
218 minutes/each). The band intensity of targeted proteins was measured using the LI-COR Odyssey FC  
219 Imaging System.

## 220 2.8. Cell death detection

221 Cell death in zebrafish eye sections was detected using DeadEnd™ fluorometric TUNEL assay  
222 (Promega, UK) according to the manufacturer's instructions. Briefly, following dewaxation  
223 zebrafish eye sections were treated with proteinase K solution (20 µg/ml), then incubated with  
224 rTDT reaction at 37°C for one hour. The reaction was terminated with 2×SSC. The sections were  
225 mounted with Vectashield DAPI (D9542-Sigma, UK) and the images were taken under ZEISS LSM  
226 800 confocal microscopy. For quantification of cell death, six sections were chosen from six eyes  
227 (one section/each eye) of control, *rpgr1* mutant or Gyp-treated *rpgr1* mutant group; in each  
228 section, a region (50 µM×20 µM, long × wide) in the superior side (0.4 mm from the optic nerve  
229 head) was chosen; TUNEL-positive photoreceptor cells in each region were counted and presented  
230 as a percentage of the total number of photoreceptor cells in the same region.

## 231 2.9. Statistical analysis

232 Statistical analysis of the data was performed using GraphPad Prism 6 software via one-way  
233 ANOVA (analysis of variance) followed by Bonferroni post hoc test. The data were calculated from  
234 at least three independent experiments and shown as mean ± SEM (standard error of the mean). A  
235 p value <0.05 was considered to be statistically significant.

## 236 3. Results

### 237 3.1. Toxic effect of Gyp on zebrafish embryos and larvae

238 Potential toxicity of Gyp was assessed to allow utilization of a safe dose for subsequent Gyp  
239 treatment. Zebrafish embryos at 6 hpf were exposed to Gyp at different concentrations (2.5, 5, 15  
240 and 25 µg/ml) for 5 days. Treatment with Gyp at 2.5 and 5 µg/ml resulted in mortality over this  
241 period that was no different to that of the control group. Higher concentrations, however, caused

242 significantly increased mortality: 15 and 25  $\mu\text{g}/\text{ml}$  Gyp resulted in, respectively,  $\sim 30\%$  and  $\sim 60\%$   
243 mortality at 120hpf (Figure S1A). The toxic effect of Gyp on cardiovascular development was  
244 studied by monitoring the heart rate in control and treated groups at 72hpf. Only 25  $\mu\text{g}/\text{ml}$  Gyp  
245 treatment had a significant effect on heart rate compared to untreated controls. Heart rate in the  
246 control group was typically  $\sim 100\text{-}120$  beats/min; a similar rate was observed in zebrafish larvae  
247 exposed to Gyp at 2.5, 5 or 15  $\mu\text{g}/\text{ml}$ , whereas the 25  $\mu\text{g}/\text{ml}$  Gyp-treated group showed a  
248 significantly reduced heart rate of  $\sim 75$  beats/min (Figure S1B). The hatching rate of zebrafish  
249 embryos incubated with Gyp at different concentrations was also monitored at 72 hpf. The  
250 hatching rate of 2.5  $\mu\text{g}/\text{ml}$  and 5  $\mu\text{g}/\text{ml}$  Gyp-treated embryos was 100%, identical to that of the  
251 controls. However, zebrafish embryos treated with 15 or 25  $\mu\text{g}/\text{ml}$  Gyp had a marked decrease in  
252 hatching rate compared to the untreated control group (Figure S1C). Based on the above toxic  
253 effects of Gyp on zebrafish embryos, we chose Gyp at 5  $\mu\text{g}/\text{mL}$  for use in subsequent treatments.

### 254 3.2. *Gyposide treatment rescued photoreceptor degeneration in *rpgrip1* mutant zebrafish*

255 We have shown previously that outer / inner segments of *rpgrip1* mutant zebrafish retina were  
256 significantly shorter compared to the wildtype retina and that most rod cells had degenerated at  
257 1mpf (Raghupathy et al., 2017). In the current study we performed retinal histology of wildtype,  
258 Gyp-treated and untreated *rpgrip1* mutant zebrafish at 1 mpf and confirmed that the  
259 photoreceptor layer of *rpgrip1* mutants was significantly shorter compared to that of wildtype  
260 zebrafish. The thickness of the wildtype photoreceptor layer was  $\sim 56$   $\mu\text{m}$ , while that of *rpgrip1*  
261 mutant zebrafish was  $\sim 36$   $\mu\text{m}$ . *Rpgrip1* mutant zebrafish treated with 5 $\mu\text{g}/\text{ml}$  Gyp had a  
262 significantly thickened photoreceptor layer of  $\sim 41$   $\mu\text{m}$ , though the thickness of photoreceptor layer

263 in Gyp-treated *rpgr1* mutant zebrafish was significantly less than that of wildtype zebrafish  
264 (Figure 1).

265 Rhodopsin has been shown to be mislocalized to the outer nuclear layer (ONL) of mouse  
266 *Rpgr1* mutant retinas ((Won et al., 2009). Immunofluorescence staining of retinal sections with  
267 4D2 antibody (detection of rhodopsin) revealed that only a weak signal of mislocalized rhodopsin  
268 was present in ONL of zebrafish *rpgr1* mutant retinas, demonstrating early rod degeneration.  
269 Treatment of *rpgr1* mutant zebrafish with Gyp resulted in significantly increased signals of 4D2  
270 staining (Figure 2A,B); when compared to wildtype, Gyp-treated zebrafish had significantly  
271 reduced 4D2 signals. *Rpgr1* mutant zebrafish also had markedly lower mRNA level of *rhodopsin*,  
272 while Gyp treatment significantly increased *rhodopsin* mRNA level although still not as high as that  
273 seen in wildtype zebrafish (Figure 2C).

### 274 3.3. Gyp reduced photoreceptor cell death in *rpgr1* mutant zebrafish

275 *Rpgr1* mutant zebrafish have been shown to display significant cell death at examined time  
276 points: 14 days post fertilization (dpf), 1 mpf and 3 mpf (Raghupathy et al., 2017). In order to  
277 examine the protective role of Gyp, we carried out TUNEL assay to assess photoreceptor cell death.  
278 We observed significantly increased cell death in the ONL of the mutant zebrafish retinas, around  
279 5-fold more compared to the control group. Gyp-exposed *rpgr1* mutant embryos showed a  
280 marked decrease in photoreceptor cell death compared to that seen in untreated *rpgr1* mutant  
281 zebrafish, while no difference was found between Gyp-treated and wildtype zebrafish (Figure 3).

282 We further examined whether the photoreceptor death was caspase-dependent by  
283 measuring the expression levels of caspase proteases, the key executioners of the apoptotic

284 process. Relative gene expression analysis using qRT-PCR showed significantly increased  
285 expression of *caspase3* in *rpgr1* mutant zebrafish eyes compared to those of wildtype zebrafish.  
286 Gyp treatment resulted in significantly decreased expression of *caspase 3* gene in the mutant  
287 zebrafish (Figure S2A). Furthermore, we examined the protein level of Caspase 3 by Western  
288 blotting and found that Caspase 3 was significantly increased in *rpgr1* mutant eyes compared to  
289 that of wildtype zebrafish, while Gyp treatment significantly counteracted these changes (Figure  
290 S2B). When compared to wildtype zebrafish, Gyp-treated mutant zebrafish still had higher  
291 expression of Caspase 3 at mRNA and protein levels (Figure S2).

#### 292 3.4. Gyp treatment can enhance the antioxidant capacity in *rpgr1* mutant eyes

293 Excessive reactive oxygen species (ROS) production causes cell death through the oxidation and  
294 damage of macromolecules. We have shown previously that Gyp can suppress H<sub>2</sub>O<sub>2</sub>-induced ROS  
295 production in retinal epithelial cells (Alhasani et al., 2018). Therefore, we conjectured that  
296 excessive ROS production underlies increased photoreceptor cell death in *rpgr1* mutant  
297 zebrafish retinas and that Gyp might reverse this effect. In fact, ROS production in *rpgr1* mutant  
298 zebrafish eyes was 2766% higher than that in wildtype zebrafish. Treatment of mutant zebrafish  
299 with Gyp resulted in a significant decrease in ROS production by 63% compared to that of  
300 untreated *rpgr1* mutant zebrafish eyes; however, even when treated with Gyp, mutant zebrafish  
301 had a higher production of ROS than did wildtype zebrafish (Figure 4A).

302 We then assessed the effect of Gyp on antioxidant gene expression using qRT-PCR. We  
303 observed that expression of *catalase*, *sod1*, *sod2*, *glutathione peroxidase 1 (gpx1)*,  
304 *glutamate-cysteine ligase modifier subunit (gclm)*, *NAD(P)H quinone oxidoreductase-1 (nqo1)* and

305 NF-E2-related factor-2 (*nrf2*) genes were markedly decreased in the mutant zebrafish eyes when  
306 compared to that of wildtype zebrafish. Gyp exposure significantly increased the expression of the  
307 examined antioxidant genes compared to that of untreated *rpgr1p1* mutant zebrafish. When  
308 compared to wildtype zebrafish, Gyp-treated zebrafish had, with the exception of *sod2*, a lower  
309 expression of the examined genes (Figure 4B-H).

310 We also measured SOD and catalase activities and the levels of glutathione (GSH) and  
311 malondialdehyde (MDA) in the eyes of wildtype, untreated and Gyp-treated *rpgr1p1* mutant  
312 zebrafish. SOD and catalase activities in *rpgr1p1* mutant zebrafish eyes were significantly decreased  
313 when compared to that of wildtype zebrafish; Gyp treatment significantly increased SOD and  
314 catalase activities compared to that of untreated *rpgr1p1* mutant zebrafish, though activities of  
315 both enzymes were still lower than that in wildtype zebrafish (Figure 5A, B). GSH level was  
316 significantly lower in *rpgr1p1* mutant zebrafish eyes compared to that of wildtype zebrafish;  
317 treatment with Gyp significantly increased GSH level compared to that of untreated *rpgr1p1*  
318 mutant zebrafish; when compared to wildtype zebrafish, Gyp-treated zebrafish eyes had a lower  
319 level of GSH (Figure 5C). The level of MDA was higher in *rpgr1p1* mutant zebrafish eyes compared  
320 to wildtype zebrafish, while Gyp treatment resulted in a significantly decreased MDA level  
321 compared to that of untreated *rpgr1p1* mutant zebrafish; compared to wildtype zebrafish, MDA  
322 level in Gyp-treated mutant zebrafish eyes was higher (Figure 5D).

### 323 3.5. Protective effect of Gypenoside against ER stress

324 ROS production and ER stress are closely related events. ER stress leads to increased transcription  
325 and translational responses, thereby causing an increased expression of ER stress inducers (Hetz et



326 al., 2011). Accordingly, we examined expression of *xbp1t* (total) and its spliced variant *xbp1s*, *atf4*,  
327 *atf6* and *bip*, all of which are induced in ER stress. Expression of all these genes was significantly  
328 higher in *rpgr1p1* mutant zebrafish eyes compared to wildtype zebrafish, while expression was  
329 significantly lower in *rpgr1p1* mutant zebrafish eyes that were treated with Gyp compared to those  
330 that were untreated. Expression of *atf6*, *xbp1s* and *xbp1t* (but not *atf4* or *bip*) remained  
331 significantly higher in mutant zebrafish treated with Gyp compared to that of wildtype zebrafish  
332 (Figure 6).

### 333 3.6. Gyp inhibited inflammation in *rpgr1p1* mutant zebrafish

334 We also examined expression of proinflammatory cytokines (*il-1 $\beta$* , *il-6* and *tnf- $\alpha$* ) using qRT-PCR  
335 and found that expression of these genes was significantly higher in *rpgr1p1* mutant zebrafish eyes  
336 compared to that of wildtype zebrafish; Gyp treatment significantly reduced expression of the  
337 three cytokines (Figure 7A). The change of Tnf- $\alpha$  protein level in Gyp-treated *rpgr1p1* mutant was  
338 also confirmed by Western blotting. Expression of the proinflammatory cytokines was higher in  
339 Gyp-treated zebrafish eyes compared with that of wildtype zebrafish eyes (Figure 7B).

## 340 4. Discussion

341 The morphological and functional retinal cell impairment observed in RP is often a result of  
342 molecular changes triggered by the retinal damage (Dias et al. 2018). This retinal degeneration  
343 might be prompted by several factors including genetic predispositions, higher intraocular  
344 pressure, increased blood glucose levels, oxidative/nitrosative stress, or even aging. Irrespective of  
345 the trigger factor, a subsequent cascade of cell signals leads to well-established morphological and  
346 functional modifications such as apoptosis and retinal remodelling (Dias et al. 2018). Moreover,

347 oxidative stress, inflammatory response and induction of apoptotic pathways are characteristic  
348 traits in RP (Guadagni et al. 2015).

349 As a result of the high metabolic activity of photoreceptors, which have the greatest  
350 oxygen consumption rate per gram of any body tissue (Ames III, 1992), oxidative stress contributes  
351 significantly to the progression of RP (Komeima et al., 2006; Shen et al., 2005; Usui et al., 2009).  
352 Numerous animal models of RP suggest that ROS is a stimulus that triggers apoptotic  
353 photoreceptor cell death in RP and is aggravated by oxidative stress (Cuenca et al., 2014). Several  
354 studies have suggested that the secondary loss of cone cells that is characteristic of RP is a result  
355 of damage arising from the higher oxygen consumption and subsequent increased ROS levels  
356 when rod cells die (Carmody and Cotter, 2000; Shen et al., 2005). Moreover, ROS production due  
357 to light exposure has been demonstrated to exacerbate retinal degeneration in hereditary and  
358 age-linked retinopathies including RP (Paskowitz et al., 2006; Sui et al., 2013).

359 Previous studies have demonstrated that Gyp enhance antioxidant capacity, inhibit  
360 inflammation and suppress apoptotic cell death in *in vivo* animal models, such as  
361 ischemia/reperfusion injury rodent models (Ye et al., 2016; Yu et al., 2016a; Yu et al. 2016b; Yu et  
362 al., 2016c; Zhao et al., 2014). More recently, Gyp have been shown to exhibit protective effects in  
363 rodent optic neuritis models by inhibiting lipopolysaccharide (LPS) or myelin oligodendrocyte  
364 glycoprotein (MOG) 35-55 peptide-induced inflammation (Wang et al., 2018; Zhang et al., 2017).  
365 There are few studies, however, on its role in retinal degeneration. Our previous *in vitro* study  
366 demonstrated that Gyp suppress ROS generation in the ARPE-19 cell line via its effects on gene  
367 expression and protein level of several antioxidant scavengers and apoptosis-related genes

368 (Alhasani et al., 2018). Our current research has shown that *rpgr1* mutant zebrafish had  
369 significantly higher production of ROS and MDA, lower expression of antioxidant genes, less GSH  
370 and high level of rod cell death; Gyp treatment significantly reduced generation of ROS and MDA  
371 and increased antioxidant gene expression and GSH level, arresting rod cell degeneration.

372         The NRF2 pathway plays an important role in cellular defence against oxidative damages  
373 (Lim et al., 2014). NRF2 is involved in the regulation of several cellular defence mechanisms that  
374 counteract the potentially lethal consequences of ROS (Lim et al., 2014). In stress-free conditions  
375 NRF2 is localized to the cytoplasm but in the presence of oxidative stress is phosphorylated and  
376 translocated to the nucleus, in turn activating several cytoprotective genes (Lim et al., 2014).  
377 Activation of the NRF2 functional pathway has been reported to protect against photoreceptor  
378 degeneration in RP animal models. Nakagami et al. (2016) demonstrated that NRF2 activation and  
379 upregulation of its effector proteins slowed photoreceptor cell death in a RP rabbit model.  
380 Adeno-associated virus (AAV)-mediated overexpression of NRF2 in the retina alleviated  
381 photoreceptor degeneration in three RP mouse models (Xiong et al., 2015). We too found that  
382 *rpgr1* mutant zebrafish eyes had lower expression of NRF2 and its targeting antioxidant genes  
383 and that Gyp treatment increased expression of these genes, suggesting that Gyp protection is  
384 possibly mediated by the NRF2 signalling pathway.

385         Impairment of protein folding and maturation in ER causes ER stress, leading to the unfolded  
386 protein response (UPR). UPR is mediated by protein kinase RNA-like endoplasmic reticulum kinase  
387 (PERK), inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) signalling  
388 pathways. ER stress has been implicated in the pathogenesis of RP, while pharmacological

389 inhibition of ER stress has been shown to slow retinal degeneration in RP animal models (Dias et  
390 al., 2018; Zhang et al., 2014). Previous studies demonstrated that Gyp protected cardiomyocytes  
391 from ischemia-reperfusion injury-induced apoptosis via inactivation of C/EBP homologous  
392 protein-10 (CHOP) (Yu et al., 2016c). Here we showed that *rpgr1* mutant eyes had higher  
393 expression of *atf4*, *atf6*, *xbp1* and *bip* genes, which encode proteins involved in the UPR. Gyp  
394 treatment led to significantly decreased expression of these genes, suggesting that Gyp inhibited  
395 ER stress that may contribute to decreased rod apoptosis in Gyp-treated *rpgr1* mutant zebrafish.

396 Inflammatory cytokines are overproduced upon exposure to ROS/oxidative stress. Several  
397 studies have reported the secretion of various proinflammatory cytokines and chemokines into  
398 the vitreous cavity in RP and other ocular diseases, with these cytokines and chemokines being  
399 partly responsible for the initiation and development of the condition (Funatsu et al., 2005;  
400 Yoshida et al., 2013a; Yoshida et al., 2013b; Yoshimura et al., 2009). Our previous study  
401 demonstrated that deletion of RPGR, an RPGRIP1 interaction protein, caused microglial activation  
402 and higher IL-1 $\beta$  expression in mouse retinas (Zhang et al., 2019). In the current study, we also  
403 found higher expression of proinflammatory cytokines (il-1 $\beta$ , il-6 and tnf- $\alpha$ ) in *rpgr1* mutant eyes  
404 and showed that Gyp significantly decreased expression of these genes.

405 In conclusion, we observed that loss of Rpgrip1 in zebrafish resulted in a defective  
406 antioxidant defense system and increased ER stress and inflammation. Gyp treatment inhibited  
407 oxidative damage, ER stress and inflammation, resulting in slowdown of photoreceptor death in  
408 *rpgr1* mutant zebrafish.

409 **Acknowledgments** This study was funded by a Saudi Arabia government PhD scholarship, the  
410 Rosetrees Trust, National Eye Research Centre and the Lotus Scholarship Program of Hunan  
411 Province, China. X.S. is a Visiting Professor to Shaoyang University.

412 **References**

413 Alhasani, R.H., Biswas, L., Tohari, A.M., Zhou, X., Reilly, J., He, J.F., Shu, X., 2018. Gypenosides  
414 protect retinal pigment epithelium cells from oxidative stress. *Food Chem. Toxicol.* 112, 76-85.

415 Ames III, A., 1992. Energy requirements of CNS cells as related to their function and to their  
416 vulnerability to ischemia: a commentary based on studies on retina. *Can. J. Physiol. Pharmacol.* 70  
417 Suppl, S158-S164.

418 Booij, J.C., Florijn, R.J., ten Brink, J.B., Loves, W., Meire, F., van Schooneveld, M.J., de Jong, P.T.,  
419 Bergen, A.A., 2005. Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1  
420 genes in patients with juvenile retinitis pigmentosa. *J. Med. Genet.* 42, e67.

421 Carmody, R.J., Cotter, T.G., 2000. Oxidative stress induces caspase-independent retinal apoptosis  
422 in vitro. *Cell Death Differ.* 7, 282-291.

423 Cuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., Pinilla, I., 2014.  
424 Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative  
425 diseases. *Prog. Retin. Eye Res.* 43, 17-75.

426 Dias, M.F., Joo, K., Kemp, J.A., Fialho, S.L., da Silva Cunha, A. Jr., Woo, S.J., Kwon, Y.J., 2018.  
427 Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical  
428 perspectives. *Prog. Retin. Eye Res.* 63, 107-131.

429 Dryja, T.P., Adams, S.M., Grimsby, J.L., McGee, T.L., Hong, D.H., Li, T., Andréasson, S., Berson, E.L.,  
430 2001. Null RPGRIP1 alleles in patients with Leber congenital amaurosis. *Am. J. Hum. Genet.* 68,  
431 1295-1298.

432 Funatsu, H., Yamashita, H., Noma, H., Mimura, T., Nakamura, S., Sakata, K., Hori, S., 2005. Aqueous  
433 humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in  
434 diabetic patients. *Graefes Arch. Clin. Exp. Ophthalmol.* 243, 3-8.

435 Gerber, S., Perrault, I., Hanein, S., Barbet, F., Ducroq, D., Ghazi, I., Martin-Coignard, D., Leowski,  
436 C., Homfray, T., Dufier, J.L., 2001. Complete exon-intron structure of the RPGR-interacting  
437 protein (RPGRIP1) gene allows the identification of mutations underlying Leber congenital  
438 amaurosis. *Eur. J. Hum. Genet.* 9, 561–571.

439 Guadagni, V., Novelli, E., Piano, I., Gargini, C., Strettoi, E., 2015. Pharmacological approaches to  
440 retinitis pigmentosa: A laboratory perspective. *Prog. Retin. Eye Res.* 48, 62-81.

441 Gupta, N., Brown, K.E., Milam, A.H., 2003. Activated microglia in human retinitis pigmentosa,  
442 late-onset retinal degeneration, and age-related macular degeneration. *Exp. Eye Res.*, 76, 463-471.

443 Hameed, A., Abid, A., Aziz, A., Ismail, M., Mehdi, S.Q., Khaliq, S., 2003. Evidence of RPGRIP1 gene  
444 mutations associated with recessive cone-rod dystrophy. *J. Med. Genet.* 40, 616– 619.

445 Hetz, C., Martinon, F., Rodriguez, D., Glimcher, L.H., 2011. The unfolded protein response:  
446 integrating stress signals through the stress sensor IRE1 $\alpha$ . *Physiol. Rev.* 91, 1219-1243.

447 Huang, L., Zhang, Q., Li, S., Guan, L., Xiao, X., Zhang, J., Jia, X., Sun, W., Zhu, Z., Gao, Y., 2013.  
448 Exome sequencing of 47 chinese families with cone-rod dystrophy: mutations in 25 known  
449 causative genes. *PLoS One.* 8, e65546.

450 Karlstetter, M., Scholz, R., Rutar, M., Wong, W. T., Provis, J. M., & Langmann, T., 2015. Retinal  
451 microglia: Just bystander or target for therapy? *Prog. Retin. Eye Res*, 45, 30–57.

452 Khan, A.O., Abu-Safieh, L., Eisenberger, T., Bolz, H.J., Alkuraya, F.S., 2013. The RPGRIP1-related  
453 retinal phenotype in children. *Br. J. Ophthalmol.* 97, 760-764.

454 Komeima, K., Rogers, B.S., Lu, L., Campochiaro, P.A., 2006. Antioxidants reduce cone cell death in a  
455 model of retinitis pigmentosa. *Proc. Natl. Acad. Sci. U S A*. 103, 11300-11305.

456 Kumaran, N., Moore, A.T., Weleber, R.G., Michaelides, M., 2017. Leber congenital  
457 amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and  
458 therapeutic interventions. *Br. J. Ophthalmol.* 101, 1147-1154.

459 Leber, T., 1869. Uber retinitis pigmentosa und angeborene amaurose. *Graefes Arch. Clin. Exp.*  
460 *Ophthalmol.* 15, 1-25.

461 Li, K., Ma, C., Li, H., Dev, S., He, J., Qu, X., 2019. Medicinal Value and Potential Therapeutic  
462 Mechanisms of *Gynostemma pentaphyllum* (Thunb.) Makino and Its Derivatives: An  
463 Overview. *Curr. Top. Med. Chem.* 19, 2855-2867.

464 Lim, J.L., Wilhelmus, M.M., de Vries, H.E., Drukarch, B., Hoozemans, J.J., van Horsen, J., 2014.  
465 Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in  
466 neurodegenerative diseases. *Arch. Toxicol.* 88, 1773-1786.

467 Mellersh, C.S., Boursnell, M.E.G., Pettitt, L., Ryder, E.J., Holmes, N.G., Grafham, D., Forman,  
468 O.P., Sampson, J., Barnett, K.C., Blanton, S., 2006. Canine RPGRIP1 mutation establishes cone – rod  
469 dystrophy in miniature longhaired dachshunds as a homologue of human Leber congenital  
470 amaurosis. *Genomics* 88, 293–301.

471 Nakagami, Y., Hatano, E., Inoue, T., Yoshida, K., Kondo, M., Terasaki, H., 2016. Cytoprotective  
472 effects of a novel Nrf2 activator, RS9, in rhodopsin Pro347Leu rabbits. *Curr. Eye Res.* 41,  
473 1123-1126.

474 Paskowitz, D.M., LaVail, M.M., Duncan, J.L., 2006. Light and inherited retinal degeneration. *Br. J.*  
475 *Ophthalmol.* 90, 1060-1066.

476 Patnaik, S.R., Zhang, X., Biswas, L., Akhtar, S., Zhou, X., Kusuluri, D.K., Reilly, J., MaySimera, H.,  
477 Chalmers, S., McCarron, J.G., Shu, X., 2018. RPGR protein complex regulates proteasome activity  
478 and mediates store-operated calcium entry. *Oncotarget* 9, 23183-23197.

479 Petrs-Silva, H., Linden, R., 2014. Advances in gene therapy technologies to treat retinitis  
480 pigmentosa. *Clin. Ophthalmol.* 8, 127-136.

481 Phelan, J.K.; Bok, D., 2000. A brief review of retinitis pigmentosa and the identified retinitis  
482 pigmentosa genes. *Mol. Vis.* 6, 116–124.

483 Raghupathy, R.K., McCulloch, D.L., Akhtar, S., Al-mubrad, T.M., Shu, X., 2013. Zebrafish model for  
484 the genetic basis of X-linked retinitis pigmentosa. *Zebrafish* 10, 62–69.

485 Raghupathy, R.K., Zhang, X., Liu, L., Alhasani, R.H., Biswas, L., Akhtar, S., Pan, L., Moens, C.B., Li, W.,  
486 Liu, M., Kennedy, B.N., Shu, X., 2017. Rpgrip1 is required for rod outer segment development and  
487 ciliary protein trafficking in zebrafish. *Sci. Rep.* 7, 16881.

488 Razmovski-Naumovski, V., Huang, T.H.W., Tran, V.H., Li, G.Q., Duke, C.C., Roufogalis, B.D., 2005.  
489 Chemistry and pharmacology of *Gynostemma pentaphyllum*. *Phytochem. Rev.* 4, 197-219.



490 Scholz, S., Fischer, S., Gündel, U., Küster, E., Luckenbach, T., Voelker, D., 2008. The zebrafish  
491 embryo model in environmental risk assessment—applications beyond acute toxicity testing.  
492 Environ. Sci. Pollut. Res. Int. 15, 394-404.

493 Shen, J., Yang, X., Dong, A., Petters, R.M., Peng, Y.W., Wong, F., Campochiaro, P.A., 2005. Oxidative  
494 damage is a potential cause of cone cell death in retinitis pigmentosa. J. Cell. Physiol. 203,  
495 457-464.

496 Sherwin, J.C., Hewitt, A.W., Ruddle, J.B., Mackey, D.A., 2008. Genetic isolates in ophthalmic  
497 diseases. Ophthalmic Genet. 29, 149-161.

498 Stone, E. M., 2007. Leber congenital amaurosis - a model for efficient genetic testing of  
499 heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 144,  
500 791-811.

501 Sui, G.Y., Liu, G.C., Liu, G.Y., Gao, Y.Y., Deng, Y., Wang, W.Y., Tong, S.H., Wang, L., 2013. Is sunlight  
502 exposure a risk factor for age-related macular degeneration? A systematic review and  
503 meta-analysis. Br. J. Ophthalmol. 97, 389-394.

504 Usui, S., Komeima, K., Lee, S.Y., Jo, Y.J., Ueno, S., Rogers, B.S., Wu, Z., Shen, J., Lu, L., Oveson, B.C.,  
505 2009. Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in  
506 retinitis pigmentosa. Mol. Ther. 17, 778-786.

507 Wang, F., Dang, Y., Wang, J., Zhou, T., Zhu, Y., 2018. Gypenosides attenuate  
508 lipopolysaccharide-induced optic neuritis in rats. Acta Histochem. 120, 340-346.

509 Won, J., Gifford, E., Smith, R.S., Yi, H., Ferreira, P.A., Hicks, W.L., Li, T., Naggert, J.K., Nishina, P.M.,  
510 2009. RPGRIP1 is essential for normal rod photoreceptor outer segment elaboration and  
511 morphogenesis. *Hum. Mol. Genet.* 18, 4329-4339.

512 Xiong, W., Garfinkel, A.E.M., Li, Y., Benowitz, L.I., Cepko, C.L., 2015. NRF2 promotes neuronal  
513 survival in neurodegeneration and acute nerve damage. *J. Clin. Invest.* 125, 1433-1445.

514 Ye, Q., Zhu, Y.I., Ye, S., Liu, H., She, X., Niu, Y., Ming, Y., 2016. Gypenoside attenuates renal  
515 ischemia/reperfusion injury in mice by inhibition of ERK signaling. *Exp. Ther. Med.* 11, 1499–1505.

516 Yoshida, N., Ikeda, Y., Notomi, S., Ishikawa, K., Murakami, Y., Hisatomi, T., Enaida, H., Ishibashi, T.,  
517 2013a. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa.  
518 *Ophthalmology* 120, e5-12.

519 Yoshida, N., Ikeda, Y., Notomi, S., Ishikawa, K., Murakami, Y., Hisatomi, T., Enaida, H., Ishibashi, T.,  
520 2013b. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa.  
521 *Ophthalmology* 120, 100-105.

522 Yoshimura, T., Sonoda, K.H., Sugahara, M., Mochizuki, Y., Enaida, H., Oshima, Y., Ueno, A., Hata, Y.,  
523 Yoshida, H., Ishibashi, T., 2009. Comprehensive analysis of inflammatory immune mediators in  
524 vitreoretinal diseases. *PLoS One* 4, e8158.

525 Yu, H., Guan, Q., Guo, L., Zhang, H., Pang, X., Cheng, Y., Zhang, X., Sun, Y., 2016a. Gypenosides  
526 alleviate myocardial ischemia-reperfusion injury via attenuation of oxidative stress and  
527 preservation of mitochondrial function in rat heart. *Cell Stress Chaperones* 21, 429–437.

528 Yu, H., Shi, L., Qi, G., Zhao, S., Gao, Y, Li, Y., 2016b. Gypenoside protects cardiomyocytes  
529 against ischemia-reperfusion injury via the inhibition of mitogen-activated protein kinase  
530 mediated nuclear factor kappa B pathway in vitro and in vivo. *Front. Pharmacol.* 7, 148.

531 Yu, H., Zhang, H., Zhao, W., Guo, L., Li, X., Li, Y., Zhang, X., Sun, Y., 2016c. Gypenoside protects  
532 against myocardial ischemia-reperfusion injury by inhibiting cardiomyocytes apoptosis via  
533 inhibition of CHOP pathway and activation of PI3K/Akt pathway in vivo and in vitro. *Cell. Physiol.*  
534 *Biochem.* 39, 123–136.

535 Zhang X., Shahani U., Reilly J., Shu X., 2019. Disease mechanisms and neuroprotection by  
536 tauroursodeoxycholic acid in Rpgr knockout mice. *J. Cell. Physiol.* 234, 18801-18812.

537 Zhang, H.K., Ye, Y., Zhao, Z.N., Li, K.J., Du, Y., Hu, Q.M., He, J.F., 2017. Neuroprotective effects of  
538 gypenosides in experimental autoimmune optic neuritis. *Int. J. Ophthalmol.* 10, 541-549.

539 Zhang, S.X., Sanders, E., Fliesler, S.J. and Wang, J.J., 2014. Endoplasmic reticulum stress and the  
540 unfolded protein responses in retinal degeneration. *Exp. Eye Res.* 125, 30-40.


541 Zhao, J., Ming, Y., Wan, Q., Ye, S., Xie, S., Zhu, Y., Wang, Y., Zhong, Z., Li, L., Ye, Q., 2014.  
542 Gypenoside attenuates hepatic ischemia/reperfusion injury in mice via antioxidative and  
543 anti-apoptotic bioactivities. *Exp. Ther. Med.* 7, 1388–1392.

544 Zhao, L., Zabel, M.K., Wang, X., Ma, W., Shah, P., Fariss, R.N., Qian H, Parkhurst, C.N., Gan, W.B.,  
545 Wong, W.T., 2015. Microglial phagocytosis of living photoreceptors contributes to inherited retinal  
546 degeneration. *EMBO Mol. Med.* 7, 1179–1197.

547 Zhao, Y., Hong, D.H., Pawlyk, B., Yue, G., Adamian, M., Grynberg, M., Godzik, A. and Li, T., 2003.  
548 The retinitis pigmentosa GTPase regulator (RPGR)-interacting protein: subserving RPGR function  
549 and participating in disk morphogenesis. *Proc. Natl. Acad. Sci. U S A*, 100, 3965-3970.

550  
551  
552  
553

554 **Figures and legends**



555

556

557

558

559

560

561

562

563

564

565



566

567

568

569

**Figure 1** (A) Representative image of hematoxylin and eosin stained transverse retinal sections of wildtype (WT), untreated (UT) *rpgrip1* mutant and Gyp-treated *rpgrip1* mutant zebrafish at 1 mph. (B) Quantification of the length of photoreceptor cell layer of the examined zebrafish. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelial cells. The data were analysed using one-way ANOVA followed by appropriate post hoc test (Bonferroni) and presented as mean  $\pm$  SEM. \*\* $p < 0.01$  and \*\*\*\* $p < 0.0001$ .



570

571

572

573

**Figure 2** (A) Immunostaining of transverse retinal sections of wildtype (WT), untreated (UT) and Gyp-treated *rpgr1* mutant zebrafish at 1mpf using 4D2 antibody. Rhodopsin localization in the rods was visualized by green fluorescent signals, while nuclei were

574 labelled in blue by staining with DAPI. (B) Quantification of the corrected total cell  
575 fluorescence (CTCF %) of rods in retinal sections of examined zebrafish. (C) Expression of  
576 *rhodopsin* was examined by qRT-PCR. INL, inner nuclear layer; ONL, outer nuclear layer.  
577 All data were analysed using one-way ANOVA followed by appropriate post hoc test  
578 (Bonferroni) and presented as mean  $\pm$  SEM. \* $p < 0.05$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

579

580

581

582

583

584

585


586

587

588

589


590



591

592 **Figure 3** (A) Photoreceptor cell death in wildtype (WT), untreated (UT) and Gyp-treated *rpgrip1*  
 593 mutant zebrafish at 1 mpf retinas was detected using TUNEL assay and photographed by ZEISS  
 594 LSM 800. (B) The number of cells labelled with positive TUNEL signal was counted within a 50  
 595  $\mu\text{m} \times 20\mu\text{m}$  (long $\times$ wide) area in the outer nuclear layer of the retinal section. The averaged  
 596 percentage of cells with positive TUNEL signal was counted from six individual animals from  
 597 each group. A negative control was set up using retinal sections from wildtype zebrafish at 1 mpf  
 598 incubated with the buffer without rTDT. INL, inner nuclear layer; ONL, outer nuclear layer. Data of  
 599 the fluorescent cells counting were analysed using one-way ANOVA followed by appropriate post  
 600 hoc test (Bonferroni) and presented as mean  $\pm$  SEM. ns, no significance. \*\*\* $P < 0.001$  and \*\*\*\* $P <$   
 601 0.0001.

602



603

604

605

606

607

608


609

610

611


**Figure 4.** (A) ROS production in eye samples of wildtype (WT), untreated (UT) or Gyp-treated *rpgrip1* mutant zebrafish at 1 mpf was measured using DCFH-DA staining described in Materials and methods section. (B-H) Expression of antioxidant genes *catalase*, *sod1*, *sod2*, *gpx1*, *gclm*, *nqo-1* and *nrf2* in the eye samples of wildtype (WT), untreated (UT) or Gyp-treated *rpgrip1* mutant zebrafish at 1 mpf was measured by qRT-PCR. All data were analysed using one-way ANOVA followed by appropriate post hoc test (Bonferroni) and presented as mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  and \*\*\*\* $p < 0.0001$ .





612  
 613 **Figure 5.** Gyp treatment significantly increased SOD (A) and catalase (B) activities and  
 614 GSH level (C), decreased MDA level (D) in eye samples of wildtype (WT), untreated (UT)  
 615 or Gyp-treated *rpgr1p1* mutant zebrafish at 1 mpf. All data were analysed by one-way  
 616 ANOVA followed by appropriate post hoc test (Bonferroni) and presented as mean  $\pm$   
 617 SEM. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

618  
 619  
 620  
 621  
 622



623

624

625

626

627

628


629

630

631

632

**Figure 6.** Expression of endoplasmic reticulum (ER) stress-related genes, *atf4* (A), *atf6* (B), *xbp1s* (C), *xbp1t* (D) and *bip* (E) in eye samples of wildtype (WT), untreated (UT) or Gyp-treated *rpgrip1* mutant zebrafish at 1 mpf was measured by qRT-PCR. All data were analysed using one-way ANOVA followed by appropriate post hoc test (Bonferroni) and presented as mean  $\pm$  SEM. ns, no significance. \*\* $p < 0.01$ , \*\*\* $p < 0.001$  and \*\*\*\* $p < 0.0001$ .



633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646

**Figure 7.** Gyp inhibited inflammation in *rpgr1p1* mutant zebrafish eyes. (A) Expression of *il-1β*, *il-6* and *tnf-α* in eye samples of wildtype, untreated (UT) or Gyp-treated *rpgr1p1* zebrafish at 1 mpf examined by qRT-PCR. (B) Protein level of Tnf-α in eye samples of wildtype, untreated (UT) or Gyp-treated *rpgr1p1* mutant zebrafish detected by Western blotting. Quantification of Tnf-α level by normalization of Tnf-α intensity to the intensity of acetylated Tubulin. All data were analysed using one-way ANOVA followed by appropriate post hoc test (Bonferroni) and presented as mean ± SEM. \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .